FOR OFFICIAL USE ONLY 187213 ACCESS DB # _____

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Robert (Rob) Shiao Examiner #: 7952 Date: 5/26/06

Art Unit: 1626 Phone Number: 2-0707 Serial Number: 10/500,317

Location (Bldg/Room#): REM (Mailbox #): 5A10 Results Format Preferred (circle): PAPER DISK

****

SCR

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Process/remedy for using Tolvaptan

Inventors (please provide full names): Ishima et al

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

1. Stuck cpd I (see claim 45)



* L1, L2 is alkylene

* R is sub

* X is a bond or O, S, N

* Ar2 is aryl

2. Stuck cpds of claim 51

****

STAFF USE ONLY

Searcher: Gar

Searcher Phone #: 22504

Searcher Location: _____

Date Searcher Picked Up: 6/1/06

Date Completed: 7/22/06

Searcher Prep & Review Time: 15

Online Time: +25

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

1 ✓ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

✓ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

___ In-house sequence systems

___ Commercial ___ Oligomer ___ Score/Length

___ Interference ___ SPDI ___ Encode/Transl

_____ Other (specify)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 187213

TO: Rei-Tsang Shiao Location: 5a10 / 5c18 Monday, May 22, 2006 Art Unit: 1626 Phone: 571-272-0707 Serial Number: 10 / 500217	From: Jan Delaval Location: Biotech-Chem Library Remsen 1a51 Phone: 571-272-2504 jan.delaval@uspto.gov

Search Notes

STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
22507, Remsen 1d86

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:55:35 ON 22 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 MAY 2006  HIGHEST RN 885029-44-7
DICTIONARY FILE UPDATES:  19 MAY 2006  HIGHEST RN 885029-44-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d l38 ide can tot

L38  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   773845-97-9  REGISTRY
ED   Entered STN:  02 Nov 2004
CN   2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
     1,3-dihydro-1,3-dimethyl-  (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C22 H26 Cl N3 O2
CI   COM
SR   CA
```



Species

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 562040-93-1 REGISTRY
ED Entered STN: 06 Aug 2003
CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
MF C22 H26 Cl N3 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (773845-97-9)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:100419

REFERENCE 2: 139:111692

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 10:55:42 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:55:42 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr tot l42

L42 ANSWER 1 OF 2 USPATFULL on STN
AN 2006:74720 USPATFULL
TI Preventives/remedies for urinary disturbance
IN Ishihara, Yuji, Itami-shi, JAPAN
Ishichi, Yuji, Sakai-shi, JAPAN
Doi, Takayuki, Osaka-shi, JAPAN
Nagabukuro, Hiroshi, Osaka-shi, JAPAN
Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
PI US 2006063769 A1 20060323
AI US 2002-500217 A1 20021226 (10)
WO 2002-JP13653 20021226
20040625 PCT 371 date
PRAI JP 2001-2004402064 20011228

JP 2002-72027 20020315
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US
CLMN Number of Claims: 6
ECL Exemplary Claim: 1-43
DRWN No Drawings
LN.CNT 13923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **562040-93-1P**
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
RN 562040-93-1 USPATFULL
CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L42 ANSWER 2 OF 2 USPATFULL on STN
AN 2005:227510 USPATFULL
TI Preventives/remedies for urinary disturbance
IN Ishihara, Yuji, Itami-shi, JAPAN
Ishichi, Yuji, Sakai-shi, JAPAN
Doi, Takayuki, Osaka-shi, JAPAN
Nagabukuro, Hiroshi, Osaka-shi, JAPAN
Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
PI US 2005197362 A1 20050908
AI US 2004-935646 A1 20040908 (10)
RLI Division of Ser. No. US 500217, PENDING A 371 of International Ser. No. WO 2002-JP13653, filed on 26 Dec 2002
PRAI JP 2001-402064 20011228
JP 2002-72027 20020315
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800,

WASHINGTON, DC, 20006-1021, US
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **562040-93-1P**
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
RN 562040-93-1 USPATFULL
CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:55:52 ON 22 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 May 2006 VOL 144 ISS 22
FILE LAST UPDATED: 19 May 2006 (20060519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr tot l41 retable

L41 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:14256 HCAPLUS
DN 142:100419
TI Preventive/remedy for urinary disturbance
IN **Doi, Takayuki; Nagabukuro, Hiroshi**
PA **Takeda Pharmaceutical Company Limited, Japan**
SO PCT Int. Appl., 258 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005000354	A1	20050106	WO 2004-JP9486	20040629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2531019	AA	20050106	CA 2004-2531019	20040629
JP 2005035996	A2	20050210	JP 2004-192142	20040629
EP 1640021	A1	20060329	EP 2004-746955	20040629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI JP 2003-188761	A	20030630		
WO 2004-JP9486	W	20040629		

AB It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by the administration of a remedy for urinary disturbance and a preventive/remedy for hyperactive bladder not accompanied by dry mouth; and a method of screening a substance preventing/treating urinary disturbance without inhibiting the urine collection function characterized by comprising measuring and comparing the acetylcholine esterase inhibitory activity and the butyrylcholine esterase inhibitory activity of a test compound A selective acetylcholine esterase inhibitory activity of 8-[3-[1-[(3-fluorphenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (I) was in vitro tested. Also, I inhibited oxybutynin-induced hyposalivation in rats.
IT **562040-93-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preventive/remedy for urinary disturbance containing selective acetylcholine esterase inhibitors)
RN 562040-93-1 HCAPLUS

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon				WO 00/18391 A1	HCAPLUS
Anon				EP 1118322 A1	HCAPLUS
Anon				JP 2001-335576 A	HCAPLUS
Anon				US 2002/0177593 A1	HCAPLUS
Anon				JP 2003-192593 A	HCAPLUS
Anon				JP 2003-201237 A	HCAPLUS
Anon				JP 2003-335701 A	HCAPLUS
Anon				EP 607864 A1	HCAPLUS
Takeda Chemical Industr	1995			JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	2000			JP 2000-169373 A	HCAPLUS
Takeda Chemical Industr	2003			WO 03/057254 A1	HCAPLUS

L41 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:551407 HCAPLUS
DN 139:111692
TI Preventives/remedies for urinary disturbance
IN **Ishihara, Yuji; Ishichi, Yuji; Doi, Takayuki ; Nagabukuro, Hiroshi; Kanzaki, Naoyuki; Ikeuchi, Motoki**
PA **Takeda Chemical Industries, Ltd., Japan**
SO PCT Int. Appl., 520 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003057254	A1	20030717	WO 2002-JP13653	20021226 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2471760	AA	20030717	CA 2002-2471760	20021226 <--
	AU 2002367425	A1	20030724	AU 2002-367425	20021226 <--
	JP 2003335701	A2	20031128	JP 2002-377956	20021226 <--
	EP 1466625	A1	20041013	EP 2002-790890	20021226 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002015389	A	20041026	BR 2002-15389	20021226 <--
	CN 1589153	A	20050302	CN 2002-828398	20021226 <--
	US 2006063769	A1	20060323	US 2004-500217	20040624 <--
	ZA 2004005123	A	20050628	ZA 2004-5123	20040628 <--
	US 2005197362	A1	20050908	US 2004-935646	20040908 <--
	JP 2006104208	A2	20060420	JP 2005-330218	20051115 <--
PRAI	JP 2001-402064	A	20011228	<--	
	JP 2002-72027	A	20020315	<--	
	JP 2004-402064	A	20011228		
	JP 2003-557611	A3	20021226		
	WO 2002-JP13653	W	20021226	<--	
	US 2004-500217	A3	20040624	<--	

OS MARPAT 139:111692

AB Preventives/remedies for urinary disturbance containing a compound having both of an acetylcholine esterase inhibitory effect and an α1 antagonistic effect which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and urinary efficiency) without affecting the urinary pressure or the blood pressure.

IT **562040-93-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)

RN 562040-93-1 HCAPLUS

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eisai Co Ltd	2000			WO 0051985 A1	HCAPLUS
Eisai Co Ltd	2000			JP 2000319258 A	HCAPLUS
Eisai Co Ltd	2001			WO 0116105 A1	HCAPLUS
Eisai Co Ltd	2001			JP 2001139547 A	HCAPLUS
Kissei Pharmaceutical C	1995			JP 07-330725 A1	HCAPLUS

Kissei Pharmaceutical C	1995		JP 07-330726 A1	HCAPLUS
Kissei Pharmaceutical C	1997		JP 09-143182 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999		AU 9894620 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999		WO 9919326 A1	HCAPLUS
Ortho-McNeil Pharmaceut	1999		JP 2002503724 A	
Ortho-McNeil Pharmaceut	1999		WO 9942448 A1	HCAPLUS
Sankyo Co Ltd	1993		JP 06-271569 A	HCAPLUS
Sankyo Co Ltd	1993		JP 06-41070 A	HCAPLUS
Sankyo Co Ltd	1993		EP 562832 A1	HCAPLUS
Takeda Chemical Industr	1994		JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	1994		EP 607864 A1	HCAPLUS
Takeda Chemical Industr	2000		WO 00018391 A1	HCAPLUS
Takeda Chemical Industr	2000		EP 1118322 A1	HCAPLUS
Takeda Chemical Industr	2000		JP 2000169373 A	HCAPLUS
Takeda Chemical Industr	2000		JP 2001335576 A	HCAPLUS

=> => fil reg
FILE 'REGISTRY' ENTERED AT 11:04:23 ON 22 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7
DICTIONARY FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d sta que l45
L43 STR







VAR G1=2/1
VAR G2=CY/18/20
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L45 73 SEA FILE=REGISTRY SSS FUL L43

100.0% PROCESSED 2212 ITERATIONS 73 ANSWERS
SEARCH TIME: 00.00.01

=> d his

(FILE 'HOME' ENTERED AT 10:43:29 ON 22 MAY 2006)
DEL HIS

FILE 'HCAPLUS' ENTERED AT 10:44:43 ON 22 MAY 2006
SET COST OFF
L1 1 S (US20060063769 OR US20050197362)/PN OR (US2004-500217# OR US2
E ISHIHARA/AU
E ISHIHARA Y/AU
L2 94 S E3
E ISHIHARA YU/AU
L3 84 S E3,E6
E YUJI/AU
L4 6 S E3
E ISHICHI/AU
L5 19 S E4,E8
E DOI/AU
L6 1 S E3
E DOI T/AU
L7 366 S E3,E4,E30
E TAKAYUKI/AU
L8 2 S E3
E NAGABUKURO/AU
L9 17 S E6,E7
E HIROSHI/AU
L10 14 S E3
E HIROSHI N/AU
L11 4 S E11
E KANXAKI/AU

```
                E KANZAKI/AU
L12           1 S E3
                E KANZAKI N/AU
L13          85 S E3,E4,E7
                E NAOYUKI/AU
                E IKEUCHI/AU
                E IKEUCHI M/AU
L14          35 S E3
                E IKEUCHI MO/AU
L15          19 S E5,E9
                E MOTOKI/AU
L16           1 S E88
                E ISHIHARA N/AU
L17          14 S E6
                E YUJI N/AU
L18          17 S E6
                E ISHICHI N/AU
                E YUJI N/AU
L19          17 S E6
                E DOI N/AU
L20          13 S E6
                E TAKAYUKI N/AU
                E NAGABUKURO N/AU
                E HIROSHI N/AU
L21           4 S E11
                E KANZAKI N/AU
L22           4 S E4
                E NAOYUKI N/AU
                E IKEUCHI N/AU
L23           7 S E4
                E MOTOKI N/AU
L24           1 S E4
L25       14848 S TAKEDA?/PA,CS
L26           1 S L1 AND L2-L24
L27           1 S L1 AND L25
L28           1 S L1,L26,L27

     FILE 'REGISTRY' ENTERED AT 10:51:33 ON 22 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 10:51:40 ON 22 MAY 2006
L29             TRA L28 1- RN :      641 TERMS

     FILE 'REGISTRY' ENTERED AT 10:51:41 ON 22 MAY 2006
L30           641 SEA L29
L31            34 S L30 AND NCNC2-C6/ES AND 46.150.18/RID AND 3/NR
L32            12 S L31 AND 3/N AND 2/O AND CL/ELS
L33             1 S L32 AND 1/NC
L34             5 S L31 AND 22/C
L35             1 S L34 AND C22H26CLN3O2
L36             1 S 773845-97-9
L37             1 S 773845-97-9/CRN
L38             2 S L36,L37

     FILE 'HCAOLD' ENTERED AT 10:54:55 ON 22 MAY 2006
L39             0 S L38

     FILE 'HCAPLUS' ENTERED AT 10:54:56 ON 22 MAY 2006
L40             2 S L38
L41             2 S L40 AND L1-L28
```

```
     FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:16 ON 22 MAY 2006
L42           2 S L38

     FILE 'REGISTRY' ENTERED AT 10:55:35 ON 22 MAY 2006

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:42 ON 22 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 10:55:52 ON 22 MAY 2006

     FILE 'REGISTRY' ENTERED AT 10:56:26 ON 22 MAY 2006
L43             STR
L44           2 S L43
L45          73 S L43 FUL
                SAV L45 TEMP SHIAO500/A
L46          71 S L45 NOT L38
L47          29 S L46 NOT L30
L48          22 S L47 AND NCNC2-C6/ES
L49           7 S L47 NOT L48
L50          42 S L46 AND L30
L51          71 S L46-L50
                SAV TEMP L51 SHIAO500A/A

     FILE 'HCAOLD' ENTERED AT 11:03:30 ON 22 MAY 2006
L52           0 S L51

     FILE 'HCAPLUS' ENTERED AT 11:03:33 ON 22 MAY 2006
L53           3 S L51
L54           2 S L53 AND L1-L25
L55           1 S L53 NOT L54

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:04:13 ON 22 MAY 2006
L56           2 S L51

     FILE 'REGISTRY' ENTERED AT 11:04:23 ON 22 MAY 2006

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 11:04:31 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:04:31 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d 156 bib abs hitrn fhitstr tot

L56  ANSWER 1 OF 2  USPATFULL on STN
AN     2006:74720  USPATFULL
TI     Preventives/remedies for urinary disturbance
IN     Ishihara, Yuji, Itami-shi, JAPAN
       Ishichi, Yuji, Sakai-shi, JAPAN
       Doi, Takayuki, Osaka-shi, JAPAN
       Nagabukuro, Hiroshi, Osaka-shi, JAPAN
       Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
       Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
PI     US 2006063769      A1   20060323
AI     US 2002-500217     A1   20021226 (10)
       WO 2002-JP13653         20021226
                               20040625  PCT 371 date
PRAI   JP 2001-2004402064  20011228
       JP 2002-72027       20020315
DT     Utility
```

FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US
CLMN Number of Claims: 6
ECL Exemplary Claim: 1-43
DRWN No Drawings
LN.CNT 13923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **562040-40-8P 562040-41-9P 562040-82-8P**
562040-83-9P 562040-85-1P 562040-86-2P
562040-88-4P 562040-89-5P 562040-90-8P
562040-91-9P 562040-92-0P 562041-73-0P
562041-74-1P 562041-75-2P 562041-76-3P
562042-03-9P 562042-07-3P 562042-11-9P
562042-14-2P 562043-03-2P 562043-18-9P
562043-19-0P 562043-20-3P 562043-21-4P
562043-22-5P 562043-37-2P 562043-40-7P
562043-41-8P 562043-42-9P
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
IT **562037-96-1P 562037-97-2P 562037-98-3P**
562038-87-3P 562038-92-0P 562038-95-3P
562039-36-5P 562039-37-6P 562039-38-7P
562039-39-8P 562039-51-4P 562039-52-5P
562039-53-6P
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
IT **562040-40-8P**
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
RN 562040-40-8 USPATFULL
CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L56 ANSWER 2 OF 2 USPATFULL on STN

AN 2005:227510 USPATFULL
TI Preventives/remedies for urinary disturbance
IN Ishihara, Yuji, Itami-shi, JAPAN
Ishichi, Yuji, Sakai-shi, JAPAN
Doi, Takayuki, Osaka-shi, JAPAN
Nagabukuro, Hiroshi, Osaka-shi, JAPAN
Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
PI US 2005197362 A1 20050908
AI US 2004-935646 A1 20040908 (10)
RLI Division of Ser. No. US 500217, PENDING A 371 of International Ser. No. WO 2002-JP13653, filed on 26 Dec 2002
PRAI JP 2001-402064 20011228
JP 2002-72027 20020315
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **562040-40-8P 562040-41-9P 562040-82-8P**
562040-83-9P 562040-85-1P 562040-86-2P
562040-88-4P 562040-89-5P 562040-90-8P
562040-91-9P 562040-92-0P 562041-73-0P
562041-74-1P 562041-75-2P 562041-76-3P
562042-03-9P 562042-07-3P 562042-11-9P
562042-14-2P 562043-03-2P 562043-18-9P
562043-19-0P 562043-20-3P 562043-21-4P
562043-22-5P 562043-37-2P 562043-40-7P
562043-41-8P 562043-42-9P
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
IT **562037-96-1P 562037-97-2P 562037-98-3P**
562038-87-3P 562038-92-0P 562038-95-3P
562039-36-5P 562039-37-6P 562039-38-7P
562039-39-8P 562039-51-4P 562039-52-5P
562039-53-6P
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
IT **562040-40-8P**
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)
RN 562040-40-8 USPATFULL
CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 11:04:44 ON 22 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 May 2006 VOL 144 ISS 22
FILE LAST UPDATED: 19 May 2006 (20060519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d l54 bib abs hitrn fhitstr retable tot

L54 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:14256 HCAPLUS
DN 142:100419
TI Preventive/remedy for urinary disturbance
IN **Doi, Takayuki; Nagabukuro, Hiroshi**
PA **Takeda Pharmaceutical Company Limited, Japan**
SO PCT Int. Appl., 258 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000354	A1	20050106	WO 2004-JP9486	20040629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

CA 2531019	AA	20050106	CA 2004-2531019	20040629
JP 2005035996	A2	20050210	JP 2004-192142	20040629
EP 1640021	A1	20060329	EP 2004-746955	20040629

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI JP 2003-188761	A	20030630	
WO 2004-JP9486	W	20040629	

AB It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity
but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by the administration of a remedy for urinary disturbance and a preventive/remedy for hyperactive bladder not accompanied by dry mouth; and a method of screening a substance preventing/treating urinary disturbance without inhibiting the urine collection function characterized by comprising measuring and comparing the acetylcholine esterase inhibitory activity and the butyrylcholine esterase inhibitory activity of a test compound A selective acetylcholine esterase inhibitory activity of 8-[3-[1-[(3-fluorphenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (I) was in vitro tested. Also, I inhibited oxybutynin-induced hyposalivation in rats.

IT **562040-40-8 562040-41-9 562040-92-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preventive/remedy for urinary disturbance containing selective acetylcholine esterase inhibitors)

IT **562040-40-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preventive/remedy for urinary disturbance containing selective acetylcholine esterase inhibitors)

RN 562040-40-8 HCAPLUS

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Anon				WO 00/18391 A1	HCAPLUS
Anon				EP 1118322 A1	HCAPLUS
Anon				JP 2001-335576 A	HCAPLUS
Anon				US 2002/0177593 A1	HCAPLUS
Anon				JP 2003-192593 A	HCAPLUS
Anon				JP 2003-201237 A	HCAPLUS
Anon				JP 2003-335701 A	HCAPLUS
Anon				EP 607864 A1	HCAPLUS
Takeda Chemical Industr	1995			JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	2000			JP 2000-169373 A	HCAPLUS
Takeda Chemical Industr	2003			WO 03/057254 A1	HCAPLUS

L64 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:551407 HCAPLUS
DN 139:111692
TI Preventives/remedies for urinary disturbance
IN **Ishihara, Yuji; Ishichi, Yuji; Doi, Takayuki ; Nagabukuro, Hiroshi; Kanzaki, Naoyuki; Ikeuchi, Motoki**
PA **Takeda Chemical Industries, Ltd., Japan**
SO PCT Int. Appl., 520 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057254	A1	20030717	WO 2002-JP13653	20021226 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2471760	AA	20030717	CA 2002-2471760	20021226 <--
	AU 2002367425	A1	20030724	AU 2002-367425	20021226 <--
	JP 2003335701	A2	20031128	JP 2002-377956	20021226 <--
	EP 1466625	A1	20041013	EP 2002-790890	20021226 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002015389	A	20041026	BR 2002-15389	20021226 <--
	CN 1589153	A	20050302	CN 2002-828398	20021226 <--
	US 2006063769	A1	20060323	US 2004-500217	20040624 <--
	ZA 2004005123	A	20050628	ZA 2004-5123	20040628 <--
	US 2005197362	A1	20050908	US 2004-935646	20040908 <--
	JP 2006104208	A2	20060420	JP 2005-330218	20051115 <--
PRAI	JP 2001-402064	A	20011228 <--		
	JP 2002-72027	A	20020315 <--		
	JP 2004-402064	A	20011228		
	JP 2003-557611	A3	20021226		
	WO 2002-JP13653	W	20021226 <--		
	US 2004-500217	A3	20040624 <--		

OS MARPAT 139:111692
AB Preventives/remedies for urinary disturbance containing a compound having both of an acetylcholine esterase inhibitory effect and an α1

antagonistic effect which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and urinary efficiency) without affecting the urinary pressure or the blood pressure.

IT **562040-40-8P 562040-41-9P 562040-82-8P**
562040-83-9P 562040-85-1P 562040-86-2P
562040-88-4P 562040-89-5P 562040-90-8P
562040-91-9P 562040-92-0P 562041-73-0P
562041-74-1P 562041-75-2P 562041-76-3P
562042-03-9P 562042-07-3P 562042-11-9P
562042-14-2P 562043-03-2P 562043-18-9P
562043-19-0P 562043-20-3P 562043-21-4P
562043-22-5P 562043-37-2P 562043-40-7P
562043-41-8P 562043-42-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)

IT **562037-96-1P 562037-97-2P 562037-98-3P**
562038-87-3P 562038-92-0P 562038-95-3P
562039-36-5P 562039-37-6P 562039-38-7P
562039-39-8P 562039-51-4P 562039-52-5P
562039-53-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)

IT **562040-40-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic compds. having acetylcholine esterase inhibitory and α1 antagonistic effects as preventives/remedies for urinary disturbance)

RN 562040-40-8 HCAPLUS

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eisai Co Ltd	2000			WO 0051985 A1	HCAPLUS
Eisai Co Ltd	2000			JP 2000319258 A	HCAPLUS

Eisai Co Ltd	2001		WO 0116105 A1	HCAPLUS
Eisai Co Ltd	2001		JP 2001139547 A	HCAPLUS
Kissei Pharmaceutical C	1995		JP 07-330725 A1	HCAPLUS
Kissei Pharmaceutical C	1995		JP 07-330726 A1	HCAPLUS
Kissei Pharmaceutical C	1997		JP 09-143182 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999		AU 9894620 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999		WO 9919326 A1	HCAPLUS
Ortho-McNeil Pharmaceut	1999		JP 2002503724 A	
Ortho-McNeil Pharmaceut	1999		WO 9942448 A1	HCAPLUS
Sankyo Co Ltd	1993		JP 06-271569 A	HCAPLUS
Sankyo Co Ltd	1993		JP 06-41070 A	HCAPLUS
Sankyo Co Ltd	1993		EP 562832 A1	HCAPLUS
Takeda Chemical Industr	1994		JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	1994		EP 607864 A1	HCAPLUS
Takeda Chemical Industr	2000		WO 00018391 A1	HCAPLUS
Takeda Chemical Industr	2000		EP 1118322 A1	HCAPLUS
Takeda Chemical Industr	2000		JP 2000169373 A	HCAPLUS
Takeda Chemical Industr	2000		JP 2001335576 A	HCAPLUS

=> d 155 bib abs hitstr retable

L55 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1956:44539 HCAPLUS
DN 50:44539
OREF 50:8606g-i,8607a-i,8608a-c
TI Synthesis of compounds related to adrenaline
AU Vaughan, James R., Jr.; Blodinger, Jack
CS American Cyanamid, Stamford, CT
SO Journal of the American Chemical Society (1955), 77, 5757-60
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable
OS CASREACT 50:44539
AB PhCH2NHMe (21.0 g.) in 100 cc. Et2O added to 22.6 g. 3,4-(MeO)2C6H3COCH2Br in 1 l. dry Et2O, the mixture allowed to stand overnight, the PhCH2NHMe.HCl (16.8 g.) filtered off, the filtrate washed with two 300-cc. portions H2O, dried, and saturated with dry HCl, and the gummy solid precipitate recrystd. from 200 cc. EtAc yielded 12.5 g. colorless needles which recrystd. twice from EtAc by Soxhlet extraction gave 11.6 g. 3,4-(MeO)2C6H3COCH2NMeCH2Ph (I), m. 184-6° (all m.ps. are corrected). I (3.35 g.) in 30 cc. EtOH hydrogenated 10 hrs. at room temperature and 50 lb. pressure over 0.2-0.3 g. 10% Pd-C, the mixture warmed, filtered hot, and cooled, and the colorless crystalline deposit (0.60 g.) recrystd. twice from 20-cc. portions EtOH gave 3,4-(MeO)2C6H3COCH2NHMe, m. 217-20° (decomposition) with softening above 211°; the original filtrate diluted with 10 cc. Et2O and the resulting precipitate (1.15 g.) recrystd. twice from 1:1 EtOH-Et2O gave 3,4-(MeO)2C6H3CH(OH) CH2NHMe, m. 114-15°. Benzimidazolone (36 g.) and 47 g. AcCl in 183 g. CS2 treated with good stirring during 15 min. with 160 g. anhydrous AlCl3, the mixture heated on the steam bath 2 hrs. with stirring, the resulting brown tarry mass poured onto 250 g. cracked ice and treated dropwise with 15 cc. concentrated HCl, the resulting brown solid washed with H2O and recrystd. with Darco from 1.5 l. 95% EtOH, and the product (30 g.) recrystd. 4 times with Darco from 95% EtOH yielded 15 g. 5-acetyl-2-benzimidazolinone (II), m. 294-5°. 3,4-(H2N)2C6H3Ac (2.4

g.) in 50 cc. dilute HCl cooled while being bubbled 10-15 min. with COCl2, and the resulting light tan precipitate (2.1 g.) recrystd. with Darco from two 100-cc. portions 95% EtOH gave 1.1 g. II, colorless plates, m. 294-5°. II (23.5 g.) dissolved with warming in 250 cc. glacial AcOH, the solution treated dropwise with stirring with 21.4 g. Br in 50 cc. glacial AcOH during 0.5 hr., the mixture heated to boiling, diluted with 250 cc. H2O, treated with Darco, and cooled, and the resulting colorless solid deposit (25.5 g.) recrystd. twice from 500-cc. portions 50% AcOH gave 16.0 g. 5-bromoacetyl-2-benzimidazolinone (III), colorless crystals, m. 264-6° (decomposition). III (4.7 g.) and 4.4 g. PhCH2NHMe in 50 cc. EtOH refluxed 2 hrs., the solution diluted with 100 cc. H2O, stirred, and cooled, the light tan solid deposit (5.1 g.) dissolved in 75 cc. dilute HCl, the solution treated with Darco, basified with excess NaOH, and cooled, the product crystallized twice more from 3% aqueous NaOH, and redissolved in EtOH, the alc. solution treated with excess alc. HCl and filtered, the filtrate diluted with Et2O, and the precipitate recrystd. twice from 75-cc. portions EtOH gave 1.5 g. 5-(N-benzyl-N-methyl-aminoacetyl)-2-benzimidazolinone-2.HCl salt (IV), colorless crystals, m. 252-4° (decomposition). IV (2.0 g.) and 0.3 g. 10% Pd-C in 30 cc. EtOH hydrogenated 18 hrs. at room temperature and 50 lb. pressure, the mixture filtered, the cake dissolved in H2O and filtered from the catalyst, the filtrate evaporated to dryness, and the solid residue (1.15 g.) dissolved in 100 cc. 50% EtOH, treated with Darco, filtered, diluted with 500 cc. Me2CO and 400 cc. EtOH, and kept in the cold gave 0.9 g. 5-(N-methylaminoacetyl)-2-benzimidazolinone HCl salt, stout colorless needles, m. above 300°; a 0.6-g. sample dissolved in 10 cc. H2O, diluted with 150 cc. EtOH and 250 cc. Me2CO, and cooled gave 0.45 g. pure material, colorless crystalline needles, m. above 300°. IV (1.32 g.) in 30 cc. H2O hydrogenated 18 hrs. at 50 lb. pressure and room temperature over 0.3 g. 10% Pd-C, the mixture filtered and evaporated to dryness, the colorless solid residue (0.85 g.) redissolved in 3 cc. hot H2O, filtered, and diluted with 75 cc. hot EtOH, and the mixture cooled yielded 0.55 g. 1-(3,4-ureylenephenyl)-2-N-methylaminoethanol HCl salt, colorless crystalline plates, decomposed above 261°; it gave recrystd. in the same manner 0.25 g. pure product, decomposing above 256°. Powdered AlCl3 (67 g.) added with good stirring during 10 min. to 13 g. 2-benzimidazolone and 23 g. PrCOCl in 76 g. CS2, the mixture heated 2 hrs. on the steam bath, the dark brown oily mixture poured onto 250 g. cracked ice, treated with 10-15 drops concentrated HCl, and filtered, the resulting brown solid filtered off, washed with H2O, and recrystd. with Darco from 400 cc. 50% EtOH, and the crude yellow product (20 g.) recrystd. twice with Darco from 50% EtOH and then 3 times from 95% EtOH gave 5.2 g. 5-butyryl-2-benzimidazolinone (V), colorless crystals, m. 261-3°. V (22.5 g.) dissolved with warming in 300 cc. glacial AcOH, the solution treated dropwise at 50-60° during 20 min. with 17.6 g. Br in 50 cc. glacial AcOH, the mixture concentrated in vacuo, and the light tan crystalline residue recrystd. from a mixture of 350 cc. EtOAc and 150 cc. EtOH gave 20.1 g. α-Br derivative (VI) of V, colorless crystals, m. 233-4° (decomposition); the filtrate concentrated to beginning crystallization and recooled gave an addnl. 8.7 g. VI, m. 233-4°; the combined crude material recrystd. gave 22.7 g. pure VI, m. 235-6° (decomposition). VI (2.8 g.) and 3.6 g. Ph2CHNH2 in 25 cc. absolute EtOH refluxed 3 hrs., the EtOH distilled off, the light yellow residue triturated with Et2O, the Et2O solution shaken with 75 cc. 10% HCl, the resulting oily phase kept several hrs. at room temperature to solidify, and the solid material (3.9 g.) recrystd. twice

from 1:1 EtOH-iso-PrOH gave 2.9 g. 5-[α-(N-benzhydrylamino)butyryl]-2-benzimidazolinone HCl salt (VII), colorless needles, m. 182-4°
VII (2.8 g.) and 0.3 g. 10% Pd-C in 30 cc. absolute EtOH hydrogenated 7 hrs. at room temperature and 50 lb. pressure, the mixture diluted with 50 cc. EtOH, heated to boiling, and filtered, the filtrate diluted with 1 l. Me2CO, and the colorless, crystalline, powdery precipitate (1.1 g.) filtered gave 1-(3,4-ureylenephenyl)-2-aminobutanol HCl salt (VIII), charred without melting between 215 and 250°, and darkened above 200°; the filtrate concentrated gave an addnl. 0.35 g. VIII. The crude VIII (1.1 g.) dissolved in 75 cc. absolute EtOH, the solution diluted with 500 cc. Me2CO and 250
cc. Et2O, and the solution cooled deposited 0.90 g. pure VIII. VIII treated with Ac2O-NaOAc gave 1-(3,4-ureylenephenyl)-2-acetamidobutyl acetate, colorless needles, m. 183-4° (from 50% EtOH). 2-Methyl-5-acetyl-benzimidazole (11.5 g.) in 100 cc. glacial AcOH irradiated at 70° with an 100-w. light bulb and treated dropwise with 10.6 g. Br in 25 cc. glacial AcOH during 4 hrs., the excess AcOH distilled off, the tarry residue stirred several hrs. with two 300-cc. portions petr. ether (b. 30-70°), and the resulting white solid recrystd. from 100 cc. 1:1-iso-PrOH gave 6.1 g. 2-methyl-5-(bromoacetyl)benzimidazole (IX) colorless granules, m. approx. 180° on rapid heating; on slow heating it darkened above 250° but did not melt below 300°.
IX (3.8 g.) and 3.6 g. PhCH2NHMe in 25 cc. EtOH refluxed 1 hr. and concentrated,
the residual red oil triturated with Et2O, the resulting solid dissolved in alc. HCl and precipitated with Et2O, this process repeated from iso-PrOH-Et2O
yielded 1.0 g. 2-methyl-5-(N-benzyl-N-methylaminoacetyl)benzimidazole (X), m. 238-40° (decomposition). Crude X (1.0 g.) in 30 cc. H2O hydrogenated 2 hrs. at 40 lb. over 0.2 g. 10% Pd-C, the solution filtered, treated with Darco, and concentrated, the crystalline residue (0.50 g.) recrystd. from 40 cc. 85%
EtOH with Darco, and the colorless solid (0.11 g.) recrystd. from 30 cc. 95% EtOH gave 0.08 g. 2-methyl-5-methylaminoacetylbenzimidazole.2HCl, colorless needles; the original alc. mother liquor (40 cc. 85% EtOH) diluted with 5-6 cc. Et2O, and the crystalline precipitate (0.2 g.) recrystd. from 50 cc. 95%
EtOH gave 1-(2-methyl-5-benzimidazolyl)-2-methylaminoethanol-2HCl, colorless needles, decomposed above 275°.

IT **853793-95-0**, 2-Benzimidazolinone, 5-[2-(diphenylmethylamino)butyryl]-, hydrochloride **853793-99-4**, 2-Benzimidazolinone, 5-(N-benzylsarcosyl)-, hydrochloride
(preparation of)

RN 853793-95-0 HCAPLUS

CN 2-Benzimidazolinone, 5-[2-(diphenylmethylamino)butyryl]-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

RN 853793-99-4 HCAPLUS
CN 2-Benzimidazolinone, 5-(N-benzylsarcosyl)-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

=> => fil reg
FILE 'REGISTRY' ENTERED AT 11:06:28 ON 22 MAY 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7
DICTIONARY FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d sca l51

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 9-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-, monohydrochloride (9CI)
MF C23 H26 Cl N3 O3 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [2-(2-chloro-4-hydroxyphenyl)ethyl][5-oxo-5-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo[4,5,1-ij]quinolin-9-yl)pentyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H34 Cl N3 O5



"Free" view of dist compounds

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[3-(2-methoxyphenyl)propyl]amino]-1-oxopentyl]-1,3-dimethyl- (9CI)
MF C24 H31 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-, monohydrochloride (9CI)
MF C25 H31 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Benzimidazolinone, 5-[2-(diphenylmethylamino)butyryl]-, hydrochloride (5CI)
MF C24 H23 N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 2H-Benzimidazol-2-one, 5-[6-[[2-(2-chlorophenyl)ethyl]amino]-2-hydroxy-1-oxohexyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
MF C23 H28 Cl N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
MF C22 H26 Cl N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 9-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro- (9CI)
MF C23 H26 Cl N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[(2-phenylethyl)amino]pentyl]-, monohydrochloride (9CI)
MF C22 H27 N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
MF C23 H28 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl-, monohydrochloride (9CI)
MF C21 H24 Cl N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl- (9CI)
MF C21 H24 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-1-methyl- (9CI)
MF C24 H28 Cl N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[1-oxo-5-[(2-

phenylethyl)amino]pentyl]-, monohydrochloride (9CI)
MF C20 H23 N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]- (9CI)
MF C21 H25 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxohexyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
MF C24 H30 Cl N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-

oxopentyl][2-[2-(trifluoromethoxy)phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H34 F3 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]- (9CI)
MF C23 H29 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-, monohydrochloride (9CI)
MF C22 H27 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-[(2-ethoxyphenyl)amino]ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
MF C24 H32 N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[3-(2-methoxyphenyl)propyl]amino]-1-oxopentyl]-1,3-dimethyl-, monohydrochloride (9CI)
MF C24 H31 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl](2-phenylethyl)-, 1,1-dimethylethyl ester (9CI)
MF C27 H35 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dimethyl- (9CI)
MF C24 H31 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI)
MF C21 H24 Cl N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl- (9CI)
MF C21 H24 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro-1-methyl-, monohydrochloride (9CI)
MF C25 H30 Cl N3 O2 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Benzimidazolinone, 5-(N-benzylsarcosyl)-, hydrochloride (5CI)
MF C17 H17 N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-1-methyl-, monohydrochloride (9CI)
MF C24 H28 Cl N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [2-(2-chloro-4-hydroxyphenyl)ethyl][5-oxo-5-(1,2,5,6-tetrahydro-1-methyl-2-oxo-4H-imidazo[4,5,1-ij]quinolin-8-yl)pentyl]-, 1,1-dimethylethyl ester (9CI)
MF C29 H36 Cl N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]- (9CI)
MF C21 H25 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dimethyl-, monohydrochloride (9CI)
MF C23 H29 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxohexyl]-1,3-dihydro-1,3-dimethyl- (9CI)
MF C24 H30 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl-, monohydrochloride (9CI)
MF C21 H24 Cl N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl- (9CI)
MF C21 H24 Cl N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro- (9CI)
MF C20 H22 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]-, monohydrochloride (9CI)
MF C21 H25 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[1-oxo-5-[(2-phenylethyl)amino]pentyl]- (9CI)
MF C20 H23 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl-, monohydrochloride (9CI)
MF C21 H24 Cl N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl][2-(2-ethoxyphenoxy)ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C29 H39 N3 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro- (9CI)
MF C24 H28 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]-, monohydrochloride (9CI)
MF C23 H29 N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro- (9CI)
MF C23 H26 Cl N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-ethoxyphenoxy)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
MF C24 H31 N3 O4 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl][2-(2-methoxyphenyl)ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H37 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]- (9CI)
MF C25 H31 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
MF C23 H28 Cl N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-

methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1-methyl- (9CI)
MF C26 H33 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1-methyl-, monohydrochloride (9CI)
MF C26 H33 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[2-[(diphenylmethyl)amino]-1-oxobutyl]-1,3-dihydro- (9CI)
MF C24 H23 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-, monohydrochloride (9CI)
MF C23 H26 Cl N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [2-(2-chloro-4-hydroxyphenyl)ethyl][5-oxo-5-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo[4,5,1-ij]quinolin-8-yl)pentyl]-, 1,1-dimethylethyl ester (9CI)
MF C28 H34 Cl N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[6-[[2-(2-chlorophenyl)ethyl]amino]-2-hydroxy-1-oxohexyl]-1,3-dihydro-1,3-dimethyl- (9CI)
MF C23 H28 Cl N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro-, monohydrochloride (9CI)
MF C24 H28 Cl N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-ethoxyphenoxy)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
MF C24 H31 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
MF C22 H26 Cl N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl- (9CI)
MF C21 H24 Cl N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[[2-[2-(trifluoromethoxy)phenyl]ethyl]amino]pentyl]- (9CI)

MF C23 H26 F3 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI)
MF C20 H22 Cl N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro-1-methyl- (9CI)
MF C25 H30 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl-, monohydrochloride (9CI)
MF C21 H24 Cl N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl][2-[(2-ethoxyphenyl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI)
MF C29 H40 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro- (9CI)
MF C21 H24 Cl N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dimethyl-, monohydrochloride (9CI)
MF C24 H31 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dimethyl- (9CI)
MF C23 H29 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[5-[[2-[(2-ethoxyphenyl)amino]ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, dihydrochloride (9CI)
MF C24 H32 N4 O3 . 2 Cl H



● 2 HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Carbamic acid, [2-(2-chlorophenyl)ethyl][5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI)
MF C27 H34 Cl N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]- (9CI)
MF C22 H27 N3 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]-, monohydrochloride (9CI)
MF C21 H25 N3 O2 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[(2-phenylethyl)amino]pentyl]- (9CI)
MF C22 H27 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[[2-[2-(trifluoromethoxy)phenyl]ethyl]amino]pentyl]-, monohydrochloride (9CI)
MF C23 H26 F3 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[methyl(phenylmethyl)amino]acetyl]-

(9CI)
MF C17 H17 N3 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 10:43:29 ON 22 MAY 2006)
DEL HIS

FILE 'HCAPLUS' ENTERED AT 10:44:43 ON 22 MAY 2006
SET COST OFF
L1 1 S (US20060063769 OR US20050197362)/PN OR (US2004-500217# OR US2
E ISHIHARA/AU
E ISHIHARA Y/AU
L2 94 S E3
E ISHIHARA YU/AU
L3 84 S E3,E6
E YUJI/AU
L4 6 S E3
E ISHICHI/AU
L5 19 S E4,E8
E DOI/AU
L6 1 S E3
E DOI T/AU
L7 366 S E3,E4,E30
E TAKAYUKI/AU
L8 2 S E3
E NAGABUKURO/AU
L9 17 S E6,E7
E HIROSHI/AU
L10 14 S E3
E HIROSHI N/AU
L11 4 S E11
E KANXAKI/AU
E KANZAKI/AU
L12 1 S E3
E KANZAKI N/AU
L13 85 S E3,E4,E7
E NAOYUKI/AU
E IKEUCHI/AU
E IKEUCHI M/AU
L14 35 S E3
E IKEUCHI MO/AU
L15 19 S E5,E9

```
                E MOTOKI/AU
L16           1 S E88
                E ISHIHARA N/AU
L17          14 S E6
                E YUJI N/AU
L18          17 S E6
                E ISHICHI N/AU
                E YUJI N/AU
L19          17 S E6
                E DOI N/AU
L20          13 S E6
                E TAKAYUKI N/AU
                E NAGABUKURO N/AU
                E HIROSHI N/AU
L21           4 S E11
                E KANZAKI N/AU
L22           4 S E4
                E NAOYUKI N/AU
                E IKEUCHI N/AU
L23           7 S E4
                E MOTOKI N/AU
L24           1 S E4
L25       14848 S TAKEDA?/PA,CS
L26           1 S L1 AND L2-L24
L27           1 S L1 AND L25
L28           1 S L1,L26,L27

     FILE 'REGISTRY' ENTERED AT 10:51:33 ON 22 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 10:51:40 ON 22 MAY 2006
L29             TRA L28 1- RN :      641 TERMS

     FILE 'REGISTRY' ENTERED AT 10:51:41 ON 22 MAY 2006
L30           641 SEA L29
L31            34 S L30 AND NCNC2-C6/ES AND 46.150.18/RID AND 3/NR
L32            12 S L31 AND 3/N AND 2/O AND CL/ELS
L33             1 S L32 AND 1/NC
L34             5 S L31 AND 22/C
L35             1 S L34 AND C22H26CLN3O2
L36             1 S 773845-97-9
L37             1 S 773845-97-9/CRN
L38             2 S L36,L37

     FILE 'HCAOLD' ENTERED AT 10:54:55 ON 22 MAY 2006
L39             0 S L38

     FILE 'HCAPLUS' ENTERED AT 10:54:56 ON 22 MAY 2006
L40             2 S L38
L41             2 S L40 AND L1-L28

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:16 ON 22 MAY 2006
L42             2 S L38

     FILE 'REGISTRY' ENTERED AT 10:55:35 ON 22 MAY 2006

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:42 ON 22 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 10:55:52 ON 22 MAY 2006

     FILE 'REGISTRY' ENTERED AT 10:56:26 ON 22 MAY 2006
```

```
L43             STR
L44           2 S L43
L45          73 S L43 FUL
                SAV L45 TEMP SHIAO500/A
L46          71 S L45 NOT L38
L47          29 S L46 NOT L30
L48          22 S L47 AND NCNC2-C6/ES
L49           7 S L47 NOT L48
L50          42 S L46 AND L30
L51          71 S L46-L50
                SAV TEMP L51 SHIAO500A/A

     FILE 'HCAOLD' ENTERED AT 11:03:30 ON 22 MAY 2006
L52           0 S L51

     FILE 'HCAPLUS' ENTERED AT 11:03:33 ON 22 MAY 2006
L53           3 S L51
L54           2 S L53 AND L1-L25
L55           1 S L53 NOT L54

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:04:13 ON 22 MAY 2006
L56           2 S L51

     FILE 'REGISTRY' ENTERED AT 11:04:23 ON 22 MAY 2006

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:04:31 ON 22 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 11:04:44 ON 22 MAY 2006

     FILE 'REGISTRY' ENTERED AT 11:06:28 ON 22 MAY 2006

=>
```